This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           June 11, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Lurbinectedin promising against ovarian cancer
Researchers at ASCO presented results of a study that assessed the anticancer activity of lurbinectedin in women with ovarian cancer that had become resistant or refractory to platinum-containing drugs, such as carboplatin or cisplatin. Overall response rate was 22 percent with lurbinectedin and 0 percent with topotecan. Lurbinectedin was more effective in platinum-resistant patients (30 percent) than in patients with the more challenging platinum-refractory cancer (6 percent).
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Ovarian cancer: Using a genetic signature to predict response to bevacizumab
Medical Research News and Interviews:
In an abstract reported at ASCO, researchers sought to determine whether a genetic “signature” could predict which patients with ovarian cancer benefit from bevacizumab. They found that that patients in the proliferative and mesenchymal groups had an 8- to 10-month improvement in outcome compared to a 3-month improvement for the immunoreactive and differentiated groups.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Test IDs ovarian cancers in which bevacizumab is no good
Medscape (Free login required)
A new gene expression biomarker test might help guide the treatment of high-grade serous ovarian cancer and avoid the futile use of an expensive type of targeted therapy. The assay may help clinicians determine which patients with HGSOC are likely to benefit from antiangiogenic drugs such as bevacizumab and which might have worse outcomes with these drugs and do better with standard chemotherapy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


Should U.S. women be screened for cervical cancer with Pap tests, HPV tests, or both?
Annals of Internal Medicine (Subscription required. First page available to non-subscribers.)
April 2014, the U.S. Food and Drug Administration approved the Cobas HPV test to be used alone to screen women aged 25 years or older for cervical cancer. A commentary in the Annals of Internal Medicine discusses the advantages and disadvantages of the newly approved test. The authors emphasize that increasing screening rates should be the major focus of efforts to reduce invasive cervical cancer regardless of which test is used.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.
Lantheus Proven Success
Discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward new breakthrough tools for the diagnosis and management of disease. MORE


Premenopausal breast cancer: Ovarian suppression with exemestane
Medical Research News and Interviews:
In premenopausal women, aromatase inhibitors given as adjuvant treatment are more effective than tamoxifen in women with hormone receptor positive early breast cancer who are given concomitantly ovarian suppression to lower estrogen production, according to an abstract presented at ASCO. The 28 percent improvement in disease free survival is comparable to that seen in postmenopausal women.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


4 new genes added to the 'inherited breast cancer' risk list
Medical News Today
Researchers at Huntsman Cancer Institute at the University of Utah have discovered four new genes that increase breast cancer risk when mutated. The team, who lead an international consortium with the aim of locating more gene mutations that may cause inherited breast cancer susceptibilities, have added RINT1, MRE11A, RAD50 and NBN to the growing list of higher risk genes.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Rare ovarian cancer leads to another: Cancer registry saves baby's life
Today Health
A young mother who survived a rare form of ovarian cancer and who wanted to help others has ended up saving the life of her own newborn son, researchers reported on Monday. Megan Flynn discovered she had a rare genetic mutation that caused her own case of ovarian cancer when she was just 17. When doctors saw it, they advised her to get her kids tested.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

June 4, 2014
June 4, 2014
May 28, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063